Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bayesian and pharmacogenetic tacrolimus dose optimization after renal transplantation
2016-000340-34Phase 4Active
- Sponsor
- Bellvitge University Hospital
- Start
- Apr 2016
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus in organ allograft rejection (2 arms), sponsored by Bellvitge University Hospital. Primary endpoints: Tacrolimus plasma concentration in therapeutic target and Percentage of patients within therapeutic target. Started Apr 2016; status: active.
02
Drugs
tacrolimus
03
Conditions
organ allograft rejection
Beyond the preview
Go deeper on 2016-000340-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000340-34.